ArticleThe Lancet. Rheumatology2025

Tumour necrosis factor inhibitor safety in rheumatoid arthritis with early-stage cancer.

Jeffrey A Sparks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.